公司资料
Lucid Diagnostics 股价、新闻与催化剂
- 股票代码:
- LUCD
- 交易所:
- NASDAQ
- 行业:
- MedTech
- 所在地:
- United States
股票表现
0.96 USD (+0.41%)
收盘价
最后更新: 2026年8月21日
196M USD
市值
股价为何变动
As of Aug 21, 2026, LUCD closed up 0.41% at $0.9643. No new same-company headline was identified in the current news window.
公司概览
Esophageal Cancer Prevention Company
Lucid Diagnostics is a commercial-stage diagnostics subsidiary of PAVmed focused on detecting esophageal precancer in patients with chronic gastroesophageal reflux disease.
EsoGuard and EsoCheck
The EsoGuard DNA test is performed on samples collected with the non-endoscopic EsoCheck cell-collection device. Together, the products are designed to identify at-risk patients before esophageal cancer develops.
Commercial and Reimbursement Model
Lucid generates revenue from processed EsoGuard tests while building adoption through gastroenterologists, health systems, commercial payers, Medicare, and the Veterans Health Administration.
未来催化剂
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。